Exchange Bulletin

Satellos Bioscience Inc. (MSCL) To Trade On Toronto Stock Exchange

February 13, 2024
Issuer: Satellos Bioscience Inc. (the "Company")
Security: Common shares
Symbol(s): MSCL
Number of securities issued and outstanding: 112,791,658
Number of securities reserved for issuance: 70,349,199
Listing category: Industrial, Non-Exempt Issuer
Trading currency: CDN$
Listing and posted for trading date: February 15, 2024 (at the opening)
Other market(s): The common shares have been listed on the TSX Venture Exchange ("TSXV") since August 18, 2021 under the symbol "MSCL". The common shares will be delisted from the TSXV on February 15, 2024, upon commencement of trading on the Toronto Stock Exchange.
Temporary market maker: Research Capital Corporation
Investor relations: Elizabeth Williams
Chief Financial Officer
(416) 648-5555
Frank Gleeson
Chief Excecutive Officer
(905) 336-6128
Incorporation: Canada Business Corporations Act
Fiscal year end: December 31
Nature of business: The Company is a biotechnology company dedicated to developing medicines to treat degenerative muscle diseases. The Company's lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy.
Transfer agent and registrar: Computershare Investor Services Inc., at its principal office in Vancouver.
Dividends: The Company does not anticipate paying cash dividends on the common shares in the foreseeable future.
Sponsorship: Not applicable.
TSX contact: Selma Thaver,
Managing Director,
TSX Listings